Evidence On Off-Label Bone Morphogenetic Protein Benefit Is Limited
This article was originally published in The Gray Sheet
Executive Summary
A draft technology assessment released April 23 by the Agency for Healthcare Research and Quality finds no evidence of improved health outcomes for most off-label uses of bone morphogenetic protein to promote bone healing following a fracture
You may also be interested in...
Medicare Advisors Set To Meet On BMPs; AHRQ Tech Assessment Issued
Evidence on the harms and benefits of bone morphogenetic protein orthopedic products will be scrutinized by Medicare advisors this week
Medicare Advisors Set To Meet On BMPs; AHRQ Tech Assessment Issued
Evidence on the harms and benefits of bone morphogenetic protein orthopedic products will be scrutinized by Medicare advisors this week
CMS asks MedCAC to consider BMPs
CMS plans a Sept. 22 meeting of its Medicare Evidence Development & Coverage Advisory Committee to consider available evidence on the clinical benefits and harms of on-label and off-label use of bone morphogenetic proteins (BMPs). The Medicare agency notes that of the more than 20 BMPs that have been identified, only four of them have demonstrated significant osteogenic properties. CMS also cites reports that up to 85% of BMP use is off-label, mostly in spine procedures, and cites a growing number of adverse events associated with BMP use. The MedCAC meeting is expected to address a draft tech assessment released in April by the Agency for Healthcare Research and Quality (1"The Gray Sheet" May 3, 2010)